Am. J. Respir. Crit. Care Med., Volume 163, Number 6, May 2001, 1314-1319

A Novel Pathophysiologic Phenomenon in Cachexic Patients with Chronic Obstructive Pulmonary Disease
The Relationship between the Circadian Rhythm of Circulating Leptin and the Very Low-Frequency Component of Heart Rate Variability

NORIAKI TAKABATAKE, HIDENORI NAKAMURA, OSAMU MINAMIHABA, MINORU INAGE, SUMITO INOUE, SHIGERU KAGAYA, MICHIYASU YAMAKI, and HITONOBU TOMOIKE

First Department of Internal Medicine, and Department of Laboratory Medicine, Yamagata University School of Medicine, Yamagata, Japan

Cachexic patients with chronic obstructive pulmonary disease (COPD) show abnormalities of the autonomic nervous system (ANS), neuroendocrine function, and energy expenditure. Leptin has been implicated in the regulation of ANS, neuroendocine function, and thermogenesis in humans. We assessed the physiologic significance of the circadian rhythm of circulating leptin using power spectrum analysis of heart rate variability (HRV) in nine cachexic male patients with COPD, eight noncachexic patients with COPD, and seven healthy control subjects. A diurnal pattern of 24-h leptin levels was present in both the control subjects (analysis of variance [ANOVA]; F = 7.80, p < 0.0001) and noncachexic COPD patients (F = 9.29, p < 0.0001), but was strikingly absent in the cachexic COPD patients (F = 2.09, p = NS). Analysis of HRV demonstrated that the diurnal rhythm of 24-h very low frequency (VLF; 0.003 to 0.04 Hz) showed significantly identical fluctuations with those of 24-h leptin levels, in all of the three groups (r = 0.388, p < 0.0001). Because VLF has been considered to reflect neuroendocrine and thermoregulatory influences, these data may suggest that the loss of circadian rhythm of circulating leptin has clinical importance in the pathophysiologic features in cachexic patients with COPD.

This article has been cited by other articles:

				P. D. Wagner Possible mechanisms underlying the development of cachexia in COPD Eur. Respir. J., March 1, 2008; 31(3): 492 - 501. [Abstract] [Full Text] [PDF]

				N. Takabatake, Y. Shibata, S. Abe, T. Wada, J.-i. Machiya, A. Igarashi, Y. Tokairin, G. Ji, H. Sato, M. Sata, et al. A Single Nucleotide Polymorphism in the CCL1 Gene Predicts Acute Exacerbations in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 875 - 885. [Abstract] [Full Text] [PDF]

				Y. Zhong, K.-M. Jan, K. H. Ju, and K. H. Chon Quantifying cardiac sympathetic and parasympathetic nervous activities using principal dynamic modes analysis of heart rate variability Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1475 - H1483. [Abstract] [Full Text] [PDF]

				R. Broekhuizen, R. F Grimble, W M. Howell, D. J Shale, E. C Creutzberg, E. F Wouters, and A. M Schols Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1{beta} -511 single nucleotide polymorphism Am. J. Clinical Nutrition, November 1, 2005; 82(5): 1059 - 1064. [Abstract] [Full Text] [PDF]

				A. G. N. Agusti Systemic Effects of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 367 - 370. [Abstract] [Full Text] [PDF]

				S. Andreas, S. D. Anker, P. D. Scanlon, and V. K. Somers Neurohumoral Activation as a Link to Systemic Manifestations of Chronic Lung Disease Chest, November 1, 2005; 128(5): 3618 - 3624. [Abstract] [Full Text] [PDF]

				N. Takabatake, M. Sata, S. Inoue, Y. Shibata, S. Abe, T. Wada, J.-i. Machiya, G. Ji, T. Matsuura, Y. Takeishi, et al. A Novel Polymorphism in Secretory Phospholipase A2-IID Is Associated with Body Weight Loss in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1097 - 1104. [Abstract] [Full Text] [PDF]

				E. F. M. Wouters Local and Systemic Inflammation in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 26 - 33. [Abstract] [Full Text] [PDF]

				T. Itoh, N. Nagaya, M. Yoshikawa, A. Fukuoka, H. Takenaka, Y. Shimizu, Y. Haruta, H. Oya, M. Yamagishi, H. Hosoda, et al. Elevated Plasma Ghrelin Level in Underweight Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 879 - 882. [Abstract] [Full Text] [PDF]

				T. Arao, N. Takabatake, M. Sata, S. Abe, Y. Shibata, T. Honma, K. Takahashi, A. Okada, Y. Takeishi, and I. Kubota In Vivo Evidence of Endothelial Injury in Chronic Obstructive Pulmonary Disease by Lung Scintigraphic Assessment of 123I-Metaiodobenzylguanidine J. Nucl. Med., November 1, 2003; 44(11): 1747 - 1754. [Abstract] [Full Text] [PDF]

				D D Sin and S F P Man Impaired lung function and serum leptin in men and women with normal body weight: a population based study Thorax, August 1, 2003; 58(8): 695 - 698. [Abstract] [Full Text] [PDF]

				A.G.N. Agusti, A. Noguera, J. Sauleda, E. Sala, J. Pons, and X. Busquets Systemic effects of chronic obstructive pulmonary disease Eur. Respir. J., February 1, 2003; 21(2): 347 - 360. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2001 Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 642 - 662. [Full Text] [PDF]

				A. L. Goldberger Heartbeats, Hormones, and Health . Is Variability the Spice of Life? Am. J. Respir. Crit. Care Med., May 1, 2001; 163(6): 1289 - 1290. [Full Text]